Suchergebnisse - "Willenbacher, Wolfgang"

PubPharm (143)

1

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: American journal of hematology | 2024

von Ludwig, H. | Melchardt, T. | Sormann, S. | +23

2

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

enthalten in: Annals of hematology | 2024

von Reimann, P. | Petzer, V. | Mündlein, A. | +19

3

In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation

enthalten in: Annals of hematology | 2024

von Brunner, A. | Thalhammer-Thurner, G. | Willenbacher, W. | +3

4

Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing

enthalten in: The Journal of allergy and clinical immunology | 2024

von Rensing-Ehl, A. | Lorenz, M. | Führer, M. | +42

5

In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation

enthalten in: Annals of hematology | 2023

von Brunner, A. | Thalhammer-Thurner, G. | Willenbacher, W. | +3

6

Nivolumab for relapsed/refractory classical Hodgkin lymphoma : 5-year survival from the pivotal phase 2 CheckMate 205 study

enthalten in: Blood advances | 2023

von Ansell, S. | Bröckelmann, P. | von Keudell, G. | +18

7

Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care : Longitudinal Observational Study

enthalten in: Journal of medical Internet research | 2023

von Lehmann, J. | de Ligt, K. | Tipelius, S. | +9

8

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma

enthalten in: European journal of haematology | 2023

von Locher, M. | Jukic, E. | Vogi, V. | +13

9

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

enthalten in: Blood | 2023

von Kreitman, R. | Moreau, P. | Ravandi, F. | +14

CommentIn: Blood. 2023 Mar 2;141(9):965-966. - PMID 36862436

10

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

enthalten in: Blood | March 2, 2023

von Kreitman, R. | Moreau, P. | Ravandi, F. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]